Related Experiment Video
Updated: Aug 7, 2026
10:46
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
[Recent progress of study on vitamin D analogs]
Atsushi Kittaka1, Nozomi Saito, Masashi Takano
1Teikyo University, Faculty of Pharmaceutical Sciences.
Clinical Calcium
|July 4, 2006
Summary
Synthetic vitamin D analogs are being developed to separate therapeutic effects from hypercalcemia. These analogs show promise for treating various conditions including cancer and immune disorders.
Area of Science:
- Endocrinology and Molecular Biology
- Medicinal Chemistry
Context:
- The natural hormone 1alpha,25-dihydroxyvitamin D(3) [1alpha,25(OH)(2)D(3)] possesses cell differentiation, antiproliferative, and immunoregulatory activities.
- Understanding the molecular mechanisms of 1alpha,25(OH)(2)D(3) action via its receptor has advanced significantly.
- A major limitation of 1alpha,25(OH)(2)D(3) is its calcemic activity, leading to hypercalcemia.
Purpose:
- To review recent advancements in the synthesis of vitamin D analogs.
- To explore strategies for separating the therapeutic benefits of vitamin D from its adverse calcemic effects.
- To highlight the therapeutic potential of novel vitamin D analogs.
Summary:
- Over 20 years of research has focused on synthetic analogs of 1alpha,25(OH)(2)D(3) to isolate its beneficial activities.
- Chemical modifications, primarily at the CD-ring side chain or A-ring, have yielded analogs with distinct pharmacological profiles.
- These synthetic analogs are being investigated for treating secondary hyperparathyroidism, psoriasis, osteoporosis, and various cancers, while mitigating hypercalcemia.
Impact:
- Development of novel therapeutics with improved safety profiles for endocrine and autoimmune diseases.
- Potential for new treatments targeting cancer and bone disorders.
- Advancement of personalized medicine through targeted vitamin D analog therapies.
